A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Inclusion Criteria

• •Patients must have had sufficient education or work experience to exclude mental retardation
• •Patients must have an abnormal cognitive performance consistent with mild cognitive impairment based on the computerized neuropsychological test battery (CANTAB Elect) that can effectively screen patients and identify cognitive deficits consistent with mild cognitive impairment
• •Patients must have evidence of amyloid deposition by means of either 1) low cerebrospinal fluid amyloid beta 1-42 (CSF amyloid beta 1-42) levels and elevated CSF p-Tau and/or total tau levels at screening (cut off values for CSF amyloid beta 1-42 and CSF p-tau and/or total tau will be based on the values established by the Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden and specified in a separate lab manual) or 2) a positive 18F-flutematol amyloid positron emission tomography (PET) amyloid scan at screening (optional depending on the site's PET capability) or both
• •Patients must have a body mass index (BMI=weight/height²) between 18 and 35 kg/m2, inclusive, at screening
• •Women must be postmenopausal, permanently sterilized or otherwise be incapable of pregnancy
• •Must adhere to required contraception during and for 3 months after study
• •Patients must be otherwise healthy for their age group or medically stable with or without medication
• •Patients must be able to be compliant with self-administration of medication
• •Patients must be able to swallow drug as a whole